New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly …

BOUDRY, Switzerland--(BUSINESS WIRE)--

Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG - News), today announced that results from three phase III studies evaluating the use of continuous REVLIMID (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine. All three publications highlight the expanding body of clinical evidence supporting lenalidomide treatment in these areas.

Continuous Lenalidomide Therapy (non-transplant eligible population):

The first article highlights a Celgene-sponsored study of continuous lenalidomide treatment in elderly patients newly diagnosed with multiple myeloma.

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015)

This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalanprednisonelenalidomide induction followed by lenalidomide maintenance (MPR-R), with melphalanprednisonelenalidomide (MPR), or melphalanprednisone (MP) followed by placebo in 459 patients aged 65 years with newly-diagnosed myeloma who were not eligible for autologous stem-cell transplant.

http://www.nejm.org/doi/full/10.1056/NEJMoa1112704

Post-transplant maintenance

The two additional articles published in the edition highlighted cooperative group studies that evaluated the use of lenalidomide maintenance following autologous stem cell transplant (ASCT).

In each of the studies, one funded by the National Cancer Institute and conducted by the Cancer and Leukemia Group B (CALGB) and one by the Intergroupe Francophone du Myelome (IFM), maintenance treatment with lenalidomide following ASCT resulted in delayed time to disease progression or death compared to placebo.

Read the original here:
New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly ...

Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy

Public release date: 9-May-2012 [ | E-mail | Share ]

Contact: Dean Forbes dforbes@fhcrc.org 206-667-2896 Fred Hutchinson Cancer Research Center

SEATTLE For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy. Initial results of the ongoing, small clinical trial of three patients with glioblastoma showed that two patients survived longer than predicted if they had not been given the transplants, and a third patient remains alive with no disease progression almost three years after treatment.

"We found that patients were able to tolerate the chemotherapy better and without negative side effects after transplantation of the gene-modified stem cells than patients in previous studies who received the same type of chemotherapy without a transplant of gene-modified stem cells," said Hans-Peter Kiem, M.D., senior and corresponding author of the study published in the May 9 issue of Science Translational Medicine.

Kiem, a member of the Clinical Research Division at the Hutchinson Center, said that a major barrier to effective use of chemotherapy to treat cancers like glioblastoma has been the toxicity of chemotherapy drugs to other organs, primarily bone marrow. This results in decreased blood cell counts, increased susceptibility to infections and other side effects. Discontinuing or delaying treatment or reducing the chemotherapy dose is generally required, but that often results in less effective treatment.

In the current study, Kiem and colleagues focused on patients with glioblastoma, an invariably fatal cancer. Many of these patients have a gene called MGMT (O6-methylguanine-DNA-methyltransferase) that is turned on because the promoter for this gene is unmethylated. MGMT is a DNA repair enzyme that counteracts the toxic effect of some chemotherapy agents like temozolomide. Patients with such an unmethylated promoter status have a particularly poor prognosis.

A drug called benzylguanine can block the MGMT gene and make tumor cells sensitive to chemotherapy again, but when given with chemotherapy, the toxic effects of this combination are too much for bone marrow cells, which results in marrow suppression.

By giving bone marrow stem cells P140K, which is a modified version of MGMT, those cells are protected from the toxic effects of benzylguanine and chemotherapy, while the tumor cells are still sensitive to chemotherapy. "P140K can repair the damage caused by chemotherapy and is impervious to the effects of benzylguanine," Kiem said.

"This therapy is analogous to firing at both tumor cells and bone marrow cells, but giving the bone marrow cells protective shields while the tumor cells are unshielded," said Jennifer Adair, Ph.D., who shares first authorship of the study with Brian Beard, Ph.D., both members of Kiem's lab.

The three patients in this study survived an average of 22 months after receiving transplants of their own circulating blood stem cells. One, an Alaskan man, remains alive 34 months after treatment. Median survival for patients with this type of high-risk glioblastoma without a transplant is just over a year.

Read more from the original source:
Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy

Angie the chimp undergoes revolutionary stem cell treatment | Video

Chimp receives stem cells 25-year-old chimp received treatments for a torn ...

Photo by Eric Hasert

ERIC HASERT/TREASURE COAST NEWSPAPERS Dr. Darrell Nazareth, of the Florida Veterinary League in Vero Beach (background) injects chimpanzee stem cells with the help of veterinarian Dr. Jocelyn Bezner, of Save the Chimps, into the knee of Angie, a 25-year-old female chimp suffering from a torn anterior cruciate ligament, at the Save The Chimps Sanctuary in Fort Pierce. The surgery was performed inside the sanctuary's mobile surgical unit, which involved extraction of fat and blood cells that were transported to the Florida Veterinary League in Vero Beach to extract approximately 2.3 billion stem cells, then returning to the chimp sanctuary to finish the one-day procedure. "It feels wonderful, I can't wait to see the results two to three weeks out," Nazareth said about performing the procedure.

Photo by Eric Hasert

ERIC HASERT/TREASURE COAST NEWSPAPERS Nicole Devlin, a laboratory technician at the Florida Veterinary League in Vero Beach, works on a procedure to remove stem cells from blood and fat removed from Angie, a female chimp at Save The Chimps Sanctuary in Fort Pierce. After the stem cells were isolated, they were transported back to the chimp sanctuary in Fort Pierce to be injected back into Angie.

FORT PIERCE A 25-year-old female chimpanzee at the Save-the-Chimps sanctuary in Fort Pierce may be able to run again, thanks to a revolutionary stem cell treatment performed on Wednesday.

Angie, one of the 271 chimpanzees that live at the 150-acre sanctuary, received the cutting-edge treatment for a torn anterior cruciate ligament in her right knee, thanks to its Florida developer, Stemlogix LLC in Weston, and the Florida Veterinary League in Vero Beach.

The procedure, which normally would cost about $2,000, uses an animal's own fat to obtain adult stem cells, which are then injected into the problem area to stimulate growth of healthy cells.

Save-the-Chimps Veterinarian Dr. Linda Gregard handled the stem cell recovery procedures. Under anesthesia, fat was removed from chimp's abdomen Wednesday morning and transported to Dr. Darrell Nazareth at the Florida Veterinary League. Nazareth then isolated stem and regenerative cells from the fat, suspended them in platelet-rich plasma and transported the stem cells back to the sanctuary for the chimp's treatment.

"Hopefully, it stops the inflammation and encourages the injury to heal," said Nazareth, who has performed a similar treatment on 15 dogs and cats from his practice. He estimates that within two to three weeks, improvement will be seen in both the chimp's mobility and pain level.

Read more:
Angie the chimp undergoes revolutionary stem cell treatment | Video

Angie the chimp undergoes revolutionary stem cell treatment

Chimp receives stem cells 25-year-old chimp received treatments for a torn ...

Photo by Eric Hasert

ERIC HASERT/TREASURE COAST NEWSPAPERS Dr. Darrell Nazareth, of the Florida Veterinary League in Vero Beach (background) injects chimpanzee stem cells with the help of veterinarian Dr. Jocelyn Bezner, of Save the Chimps, into the knee of Angie, a 25-year-old female chimp suffering from a torn anterior cruciate ligament, at the Save The Chimps Sanctuary in Fort Pierce. The surgery was performed inside the sanctuary's mobile surgical unit, which involved extraction of fat and blood cells that were transported to the Florida Veterinary League in Vero Beach to extract approximately 2.3 billion stem cells, then returning to the chimp sanctuary to finish the one-day procedure. "It feels wonderful, I can't wait to see the results two to three weeks out," Nazareth said about performing the procedure.

Photo by Eric Hasert

ERIC HASERT/TREASURE COAST NEWSPAPERS Nicole Devlin, a laboratory technician at the Florida Veterinary League in Vero Beach, works on a procedure to remove stem cells from blood and fat removed from Angie, a female chimp at Save The Chimps Sanctuary in Fort Pierce. After the stem cells were isolated, they were transported back to the chimp sanctuary in Fort Pierce to be injected back into Angie.

FORT PIERCE A 25-year-old female chimpanzee at the Save-the-Chimps sanctuary in Fort Pierce may be able to run again, thanks to a revolutionary stem cell treatment performed on Wednesday.

Angie, one of the 271 chimpanzees that live at the 150-acre sanctuary, received the cutting-edge treatment for a torn anterior cruciate ligament in her right knee, thanks to its Florida developer, Stemlogix LLC in Weston, and the Florida Veterinary League in Vero Beach.

The procedure, which normally would cost about $2,000, uses an animal's own fat to obtain adult stem cells, which are then injected into the problem area to stimulate growth of healthy cells.

Save-the-Chimps Veterinarian Dr. Linda Gregard handled the stem cell recovery procedures. Under anesthesia, fat was removed from chimp's abdomen Wednesday morning and transported to Dr. Darrell Nazareth at the Florida Veterinary League. Nazareth then isolated stem and regenerative cells from the fat, suspended them in platelet-rich plasma and transported the stem cells back to the sanctuary for the chimp's treatment.

"Hopefully, it stops the inflammation and encourages the injury to heal," said Nazareth, who has performed a similar treatment on 15 dogs and cats from his practice. He estimates that within two to three weeks, improvement will be seen in both the chimp's mobility and pain level.

See the original post:
Angie the chimp undergoes revolutionary stem cell treatment

Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage

Public release date: 9-May-2012 [ | E-mail | Share ]

Contact: Emma Mason wordmason@mac.om European Society for Radiotherapy and Oncology (ESTRO)

Barcelona, Spain: Researchers believe they may have found a way to avoid damaging salivary glands during radiotherapy treatment for head and neck cancer a discovery that could improve the quality of life of 500,000 patients a year worldwide with the disease.

Presenting their findings to the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO31) [1], the researchers said that they had discovered that the stem cells essential for regenerating the parotid gland (the largest pair of salivary glands) were located mainly in its major ducts, and that these could easily be avoided during radiotherapy or given a minimal radiation dose. "This would significantly reduce complications arising from radiotherapy for head and neck cancer," said Dr Peter van Luijk, a research associate at the University Medical Center Groningen, The Netherlands.

Around 40% of patients treated for head and neck cancer suffer from the distressing side-effects of dry mouth syndrome a condition that can occur when the parotid gland stops working properly after radiation damage. This causes problems with eating, sleeping, speech, tooth loss and oral hygiene, leading to diminished quality of life, social isolation and difficulty in continuing work. Attempts to treat dry mouth syndrome and its consequences can cost hundreds or even thousands of Euros per patient per year and are mostly insufficient.

Dr van Luijk said: "Parotid gland dysfunction after radiotherapy for head and neck cancer was, and still is, a major clinical problem. During radiotherapy, attempts to minimise the risk of this complication have been aimed at reducing the average dose to the salivary gland, on the assumption that it would not make a difference where in the gland the radiation dose was reduced. However, this does not seem logical according to the anatomy of the salivary gland and, in previous work, we discovered that reductions in the radiotherapy dose to some parts of the gland allowed the parotid gland to regenerate, whereas a dose to other parts did not. Therefore, we decided to investigate the reason for these regional differences. We hypothesised that our observations could be explained by a non-uniform distribution of stem cells necessary for the long-term maintenance of organ function and affected by irradiation."

Dr van Luijk and his colleagues investigated the location of stem cells and the effects of radiotherapy to particular regions of the gland first in mouse and rat models, and then in parotid and salivary gland tissue taken from patients (after informed consent) undergoing a neck dissection for head and neck cancer.

They found that in mouse, rat and human tissue, the stem cells were predominately located in the major ducts of the parotid gland. "We have found in previous work that these stem cells are capable of regenerating a parotid gland when they have been transplanted after irradiation," said Dr van Luijk.

Dissection of the rat parotid gland and culturing of the different parts of the gland in Petri dishes showed that a greater concentration of stem cells capable of regenerating the gland were located in the centre, where the largest ducts are located. The researchers then directed high-precision irradiation at this centre part in living rats and found that it resulted in excessive reduction of saliva production, in contrast to the minimal effects observed after irradiating other parts of the gland.

Dr van Luijk explained: "The position of the stem cells in rats corresponds to the cranio-ventral extension of the gland in humans, where the excretory duct leaves the gland on the ventral, or outward-facing side. So even though the glands have different shapes in rats and humans, the stem cells are in the exact same anatomical structure."

See more here:
Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage

Successful stem cell differentiation requires DNA compaction, study finds

ScienceDaily (May 11, 2012) New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.

Researchers from the Georgia Institute of Technology and Emory University found that chromatin compaction is required for proper embryonic stem cell differentiation to occur. Chromatin, which is composed of histone proteins and DNA, packages DNA into a smaller volume so that it fits inside a cell.

A study published on May 10, 2012 in the journal PLoS Genetics found that embryonic stem cells lacking several histone H1 subtypes and exhibiting reduced chromatin compaction suffered from impaired differentiation under multiple scenarios and demonstrated inefficiency in silencing genes that must be suppressed to induce differentiation.

"While researchers have observed that embryonic stem cells exhibit a relaxed, open chromatin structure and differentiated cells exhibit a compact chromatin structure, our study is the first to show that this compaction is not a mere consequence of the differentiation process but is instead a necessity for differentiation to proceed normally," said Yuhong Fan, an assistant professor in the Georgia Tech School of Biology.

Fan and Todd McDevitt, an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, led the study with assistance from Georgia Tech graduate students Yunzhe Zhang and Kaixiang Cao, research technician Marissa Cooke, and postdoctoral fellow Shiraj Panjwani.

The work was supported by the National Institutes of Health's National Institute of General Medical Sciences (NIGMS), the National Science Foundation, a Georgia Cancer Coalition Distinguished Scholar Award, and a Johnson & Johnson/Georgia Tech Healthcare Innovation Award.

To investigate the impact of linker histones and chromatin folding on stem cell differentiation, the researchers used embryonic stem cells that lacked three subtypes of linker histone H1 -- H1c, H1d and H1e -- which is the structural protein that facilitates the folding of chromatin into a higher-order structure. They found that the expression levels of these H1 subtypes increased during embryonic stem cell differentiation, and embryonic stem cells lacking these H1s resisted spontaneous differentiation for a prolonged time, showed impairment during embryoid body differentiation and were unsuccessful in forming a high-quality network of neural cells.

"This study has uncovered a new, regulatory function for histone H1, a protein known mostly for its role as a structural component of chromosomes," said Anthony Carter, who oversees epigenetics grants at NIGMS. "By showing that H1 plays a part in controlling genes that direct embryonic stem cell differentiation, the study expands our understanding of H1's function and offers valuable new insights into the cellular processes that induce stem cells to change into specific cell types."

During spontaneous differentiation, the majority of the H1 triple-knockout embryonic stem cells studied by the researchers retained a tightly packed colony structure typical of undifferentiated cells and expressed high levels of Oct4 for a prolonged time. Oct4 is a pluripotency gene that maintains an embryonic stem cell's ability to self-renew and must be suppressed to induce differentiation.

"H1 depletion impaired the suppression of the Oct4 and Nanog pluripotency genes, suggesting a novel mechanistic link by which H1 and chromatin compaction may mediate pluripotent stem cell differentiation by contributing to the epigenetic silencing of pluripotency genes," explained Fan. "While a significant reduction in H1 levels does not interfere with embryonic stem cell self-renewal, it appears to impair differentiation."

Go here to read the rest:
Successful stem cell differentiation requires DNA compaction, study finds

Stem cell shield may protect body from chemotherapy side effects

A new study suggests stem cells may be able to act as a shield to protect the body from the harmful side effects of chemotherapy, the BBC News reported.

As chemotherapy drugs attempt to kill cancer drugs, they can also affect the bone marrow and other healthy tissues.

In a new study, however, researchers from the Fred Hutchinson Cancer Research Center in Seattle were able to use genetically modified stem cells to protect the bone marrow.

The bone marrow is very susceptible to chemotherapy, and in response to the treatment, produces less blood cells. This leaves the body more prone to infection and fatigue.

Stem cell shielding appeared to stave off some of these negative side effects. Researchers took bone marrow from patients with brain cancer and isolated the stem cells. They infected the cells with a virus which carried a gene to protect the cells against a chemotherapy drug, and then re-implanted the cells into the patients.

"We found that patients were able to tolerate the chemotherapy better, and without negative side effects, after transplantation of the gene-modified stem cells than patients in previous studies who received the same type of chemotherapy without a transplant of gene-modified stem cells, Professor Hans-Peter Kiem told the BBC News.

All three patients lived longer than the average survival time of 12 months. One patient was still alive 34 months after treatment, according to the BBC.

Click here to read more from the BBC News.

Link:
Stem cell shield may protect body from chemotherapy side effects

2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes

Public release date: 8-May-2012 [ | E-mail | Share ]

Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Tampa, Fla. (May. 8, 2012) Two studies appearing in a recent issue of Cell Transplantation (20:11-12), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, evaluate stem cells derived from dental tissues for characteristics that may make them therapeutically useful and appropriate for transplantation purposes.

Induced pluripotent stem cells from immature dental pulp stem cells

A Brazilian and American team of researchers used human immature dental pulp stem cells (IDPSCs) as an alternative source for creating induced pluripotent stem cells (iPSCs), stem cells that can be derived from several kinds of adult tissues. According to the study authors, production of iPSCs "opens new opportunities for increased understanding of human genetic diseases and embryogenesis" and will likely have a "great impact on future drug screening and toxicology tests."

The authors note, however, that the reprogramming methodology for making iPSCs is relatively new and "needs refining" in terms of technique, efficiency and cell type choice.

The researchers report that they easily, and in a short time frame, programmed human immature dental pulp stem cells into iPSCs with the hallmarks of pluripotent stem cells.

"Human IDPSCs can be easily derived from dental pulp extracted from adult or 'baby teeth' during routine dental visits," said study lead author Dr. Patricia C.B. Beltrao-Braga of the highly ranked National Institute of Science and Technology in Stem and Cell Therapy in Ribeirao Preto, Brazil. "hIDPSCs are immunologically privileged and can be used in the absence of any immune suppression protocol and have valuable cell therapy applications, including reconstruction of large cranial defects."

Contact: Dr. Patricia C.B. Beltrao-Braga, National Institute of Science and Technology in Stem Cell and Cell Therapy, 2051 Tenente Catao Roxo St. Ribeirao Preto, Brazil. Tel. 55 (11) 3091-7690 Email patriciacbbbraga@usp.br

Citation: Beltro-Braga, P. C. B.; Pignatari, G. C.; Maiorka, P. C.; Oliveira, N. A. J.; Lizier, N. F.; Wenceslau, C. V.; Miglino, M. A.; Muotri, A. R.; Kerkis, I. Feeder-free derivation of induced pluripotent stem cells from human immature dental pulp stem cells. Cell Transplant. 20(11-12):1707-1719;2011.

Go here to see the original:
2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes

Navigating the IP Minefield of Human Embryonic Stem Cell Development

FARMINGTON, Conn., May 8, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports

Opportunities in Human Embryonic Stem Cell (hESC) ProductsHuman embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, the stage reached 4 to 5 days after fertilization. They are the most pluripotent of all stem cell types, able to develop into any of over 200 different cell types in the human body, rending them tremendously useful for their therapeutic potential. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for guidance for companies seeking to develop new products.

BioInformant's new Opportunities in Human Embryonic Stem Cell (hESC) Products market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market. Over the past 15 years, WARF has been the major "gatekeeper" in determining which research product companies are able to conduct research, create commercial products, and develop novel therapies using hESCs. To date, WARF has entered into licensing agreements with only 27 commercial partners for its intellectual portfolio related to isolating and differentiating hESCs.

While Invitrogen, Becton Dickinson and Chemicon have disclosed licensing agreements with WARF, many research products companies have be forced to explore less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species. This report will give readers a fuller, more complete understanding of the complex IP situation in the hESC market, before they make any costly development decisions.

An Executive Summary for this report and a free sample of the full document are available at http://www.giiresearch.com/report/biof239705-opportunities-human-embryonic-stem-cell-hesc.html

Capitalizing on Opportunities in Cord Blood Industry GrowthFor even greater depth, companies involved in regenerative medicine research and development can turn to BioInformant's Cord Blood Industry Opportunities report to help guide future research and product design to ensure strong future sales and growth.

BioInformant's new market report "Capitalizing on Cord Blood Industry Growth" is particularly useful because it provides a direct link into the minds of a large, global population of parents, offering findings that have not been made available previously. This report also offers the most complete overview available anywhere of active global cord blood banks, tracking all 521 specific Cord Blood Banks operating in the world today.

An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/biof234290-capitalizing-on-opportunities-cord-blood-industry.html

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

Go here to read the rest:
Navigating the IP Minefield of Human Embryonic Stem Cell Development

Fluidigm and the Broad Institute Establish Single-Cell Genomics Research Center

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

The Broad Institute and Fluidigm Corporation (NASDAQ:FLDM - News) today announced the launch of a new research center dedicated to accelerating the development of research methods and discoveries in mammalian single-cell genomics. The Single-Cell Genomics Center is also expected to act as a hub for collaboration among single-cell genomics researchers in many pioneering fields, including stem cells and cancer biology.

The Center will be housed at the Broad Institute in Cambridge, Massachusetts and will feature a complete suite of Fluidigm single-cell tools, protocols and technologies, most notably the BioMark HD System. The Center grew out of ongoing collaborations between the Broad Institute and Fluidigm that bridge multiple genomic platforms.

With the Single-Cell Genomics Center, we will enable researchers to access the exciting new world of single-cell genomics, catalyze discoveries and advance our understanding of this important area of biology, said Wendy Winckler, Ph.D., Director of the Genetic Analysis Platform at the Broad Institute.

The cell is the fundamental unit of life, and through greater understanding of it, researchers can make breakthroughs in large and important fields, such as cancer diagnosis and therapy, stem cell biology, vaccine development, and even the mounting battle against drug-resistant bacteria. We expect this center to inspire, enable and accelerate efforts in the emerging field of single-cell research, said Gajus Worthington, President and Chief Executive Officer of Fluidigm.

Researchers have long known that heterogeneity exists among cells in tissue samples and other populations, but this cellular variability is masked by averaging data across pooled cell samples. The ability to tease out single-cell genomic data has historically been limited by a lack of standardized, user-friendly methods that would allow the broader biological and clinical communities to study individual cellular variability at high definition, high throughput, and low cost. Advances in technology, such as Fluidigms microfluidic chips and high-throughput instruments, have made single-cell studies feasible by converting cellular heterogeneity from a source of background noise to a source of information enabling cutting-edge discoveries.

Fluidigms technology provides the capabilities required to analyze single cells: microfluidics and sensitivity at the nanoscale level; parallel processing of a large number of cells; and interrogation of a large number of gene targets. This unique combination of technological capabilities has fueled an upsurge in single-cell research and propelled Fluidigm technology into a leadership position in supplying tools to single-cell genomic researchers.

Through this collaborative effort, the Center intends to develop novel single-cell, microfluidic approaches for gene expression profiling, RNA/DNA sequencing and epigenetic analysis. The goal of these efforts is to make single-cell research accessible to the greater scientific community by developing and disseminating new workflows, reagents, bioinformatics tools, and data sets. These advances will allow deeper exploration of the underlying causes of many diseases, including the progression of individual cancers, differential immune responses, and the maturation of stem cells.

Our intent is to establish the Center as a focal point to enhance collaboration and accelerate the science, applications, methods and discoveries in single-cell genomics research, said Ken Livak, Ph.D., Fluidigm Senior Scientific Fellow, who will act as the Alliance Manager at the Broad Institute, overseeing research projects amongst the Center and project partners. Our efforts with the Broad Institute in forming a center that specifically focuses on single-cell research represent a big step forward for this emerging area of biological research, Livak concluded.

Fluidigm equipment is currently being installed at the Center and first proposals for projects are being solicited from the Broad community of researchers. It is expected that the Single-Cell Genomics Center will become fully operational this quarter.

See original here:
Fluidigm and the Broad Institute Establish Single-Cell Genomics Research Center